Hangzhou Valgen Medtech Co., Ltd. — Cyborg Score 7/10

Strong
Transcatheter valve repair devices

Strategic Profile

Valgen Medtech specializes in interventional treatment products for mitral and tricuspid valve repair, offering solutions including transcatheter mitral valve repair systems, radiation protection screens, balloon dilation catheters, and septal puncture systems. In November 2023, Venus MedTech and Valgen Medtech reached a consensus on signing a letter of intent for exclusive cooperation on strategic marketing for the DragonFly™ Transcatheter Mitral Valve Repair System.

Cyborg Score Rationale

Valgen demonstrates strong positioning in structural heart disease intervention with breakthrough technology (DragonFly™ approved in China in November 2023), significant IP portfolio (600+ patent applications), and strategic partnerships with established market players like Venus Medtech. Challenges include limited public financial data and reliance on China's regulated market environment.

Top Insights

  • DragonFly™ Transcatheter Mitral Valve Repair System achieved NMPA marketing approval in November 2023, marking entry into commercial phase in China's cardiovascular device market
  • Extensive IP protection with 600+ patent applications (200+ granted) covering fundamental principles and core innovations in valve repair technology
  • Strategic partnership with Venus Medtech (November 2023) provides access to network of ~500 tertiary hospitals and established clinical training infrastructure in China
  • R&D intensive organization with ~280 employees, 20% holding master's or doctoral degrees, positioned for continuous product innovation in high-complexity interventional cardiology

Named Competitors

  • Mitraclip — Transcatheter mitral valve repair system
  • Cardioband — Transcatheter mitral and tricuspid valve repair
  • Venus A-Plus — Transcatheter valve repair systems in China

Recent Developments

  • (November 2023) DragonFly™ Transcatheter Mitral Valve Repair System granted marketing approval by China's NMPA
  • (November 2023) Signed letter of intent with Venus Medtech for exclusive cooperation on strategic marketing and commercial distribution
  • (2023) Applied for more than 600 patents worldwide with 200+ patents granted

Open the full interactive Hangzhou Valgen Medtech Co., Ltd. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →